Development and assessment of 153Sm-zoledronate complex as a possible bone pain palliative agent

In this work, 153Sm-zoledronate (153Sm-ZLD) was studied using computational chemistry methods and prepared for possible use in bone pain palliation therapy.
The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state using computational chemistry methods followed by 153Sm-ZLD complex production, stablity, hydroxyapatite (HA) tests and also biodictribution studies in animals were studied and used for absorbed dose determination in critical organs.
The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state and computational chemistry methods showed that 1:1, 1:2 and 1:3 complex formation are possible in aqueous solution. 153Sm-ZLD complex was prepared with >99% radiochemical purity (ITLC, HPLC) and specific activity of 4.4 GBq/mmol. It was stable for 24h with >95% binding to HA with accumulation in rat bones and kidneys. Absorbed dose showed kidney and osteogenic tissue as critical organs.
The 153Sm-ZLD complex data were compared to 153Sm-EDTMP and 153Sm-BPAMD.